Related Experiment Video
Updated: Mar 23, 2026
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
The effect of NOD2 on the microbiota in Crohn's disease
Mackenzie L Lauro1, Jason M Burch1, Catherine Leimkuhler Grimes1
1University of Delaware, Department of Chemistry & Biochemistry, Newark, DE 19716, United States.
Abstract:
Recent advancements toward the treatment of Crohn's disease (CD) indicate great promise for long-term remission. CD patients suffer from a complex host of dysregulated interactions between their innate immune system and microbiome. The most predominant link to the onset of CD is a genetic mutation in the innate immune receptor nucleotide-binding oligomerization domain-containing 2 (NOD2). NOD2 responds to the presence of bacteria and stimulates the immune response. Mutations to NOD2 promote low diversity and dysbiosis in the microbiome, leading to impaired mucosal barrier function. Current treatments suppress the immune response rather than enhancing the function of this critical protein. New progress toward stabilizing NOD2 signaling through its interactions with chaperone proteins holds potential in the development of novel CD therapeutics.
Insights
New research suggests stabilizing nucleotide-binding oligomerization domain-containing 2 (NOD2) signaling could offer novel Crohn
Area of Science:
- Immunology and Microbiology
- Gastroenterology
- Genetic Medicine
Background:
- Crohn's disease (CD) involves complex immune system and microbiome dysregulation.
- Genetic mutations in nucleotide-binding oligomerization domain-containing 2 (NOD2) are strongly linked to CD onset.
- NOD2 mutations disrupt the microbiome, impairing mucosal barrier function.
Purpose of the Study:
- To explore novel therapeutic strategies for Crohn's disease.
- To investigate the potential of enhancing NOD2 protein function for CD treatment.
- To identify new approaches beyond immune suppression.
Main Methods:
- Analysis of NOD2 signaling pathways.
- Investigation of NOD2 interactions with chaperone proteins.
- Exploration of microbiome-host interactions in CD.
Main Results:
- Current CD treatments focus on immune suppression, not enhancing NOD2 function.
- Stabilizing NOD2 signaling via chaperone interactions shows therapeutic promise.
- Dysbiosis and impaired mucosal barrier function are linked to NOD2 mutations.
Conclusions:
- Targeting NOD2 signaling represents a promising avenue for Crohn's disease therapeutics.
- Enhancing NOD2 function, rather than solely suppressing the immune response, could lead to long-term remission.
- Further research into NOD2-chaperone interactions may yield novel CD treatments.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Microbiota of the Large Intestine
01:18Functions of the Gut Microbiota
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...